Diabetes and Obesity Drug Pharmaceutical and Healthcare Market Forecast Report 2017
May 9, 2017
WiseGuyReports.com adds Exclusive Research on “Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment” reports to its database.
Pune, India - May 9, 2017 /MarketersMedia/ —
Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.
A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/822686-global-diabetes-and-obesity-weight-loss-treatment
Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.
The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.
Scope
What are the current treatment options for diabetes and obesity?
What are the common molecular targets of pipeline therapies, and how strongly do they overlap with the current market?
Will the pipeline address unmet needs such as a lack of safe treatment options for diabetes and obesity patients?
Which late-stage pipeline products are likely to impact the current market?
How are revenues of key companies, targets and molecule types anticipated to change over the forecast period?
Which companies are anticipated to be the most prominent players over the next seven years?
How do licensing and co-development deals compare between diabetes and obesity?
Reasons to Buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the diabetes and obesity market in terms of the clinical and commercial standing of current dominant therapies. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the diabetes and obesity pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There is a strong contrast in the amount of pipeline activity for diabetes and obesity.
Analyze how individual company, molecule type and molecular target revenues are anticipated to change over the forecast period, highlighting prominent companies and the most promising molecule types and targets.
Identify which companies are the current key players for the disease cluster, and how this pattern is anticipated to change over the forecast period.
Identify commercial opportunities in the diabetes and obesity deals landscape by analyzing trends in licensing and co-development deals by stage of development, molecule type and molecular target.
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 11
2.3 Etiology and Pathophysiology11
2.4 Comorbidities and Complications 13
2.5 Epidemiology Patterns and Forecasts across the 7MM 14
2.6 Treatment 17
3 Key Marketed Products 22
3.1 Overview 22
3.2 Diabetes – Top Eight Key Marketed Products 23
3.3 Obesity Overview 31
3.3.1 Saxenda (liraglutide) 3
3.3.2 Belviq (lorcaserin hydrochloride) 33
3.3.3 Xenical (orlistat) 34
3.3.4 Contrave (bupropion hydrochloride plus naltrexone) 34
3.4 Conclusion 35
4 Pipeline Landscape Assessment 36
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/822686-global-diabetes-and-obesity-weight-loss-treatment
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: NORAH TRENT
Email: [email protected]
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349
For more information, please visit http://www.wiseguyreports.com
Source: MarketersMedia
Release ID: 196178
More News
South Korea’s chipmakers are raking it in. Can China close the gap?
South Korean memory chip giant SK Hynix kept almost 80 per cent of its total sales as operating profit last quarter, a margin almost unheard of in manufacturing, as the country’s chipmakers reap the rewards of the global artificial intelligence boom. Operating profit, defined as earnings from the company’s core business before interest and taxes, soared 632 per cent in the three months to September from a year earlier to 83.33 trillion won (US$62.76 billion) on revenue of 104.62 trillion won, SK...
U.S. Restricts Trade With Chinese Genomics Company
The move will block shipments from BGI, a major Chinese firm that U.S. officials allege is associated with forced labor and the abuse of minority groups.
Tokayev Proposes Dipping Into National Fund to Turn Kazakhstan into a ‘Big Construction Site’
In his annual state of the nation address, Tokayev laid out an ambitious spending spree focused on infrastructure and investment.
Lula’s Election Win in Brazil Is a Relief for China
Lula’s victory secures the most important destination for Chinese foreign direct investment in the Western Hemisphere and ends a winning streak for Trump-supported candidates.
Hegseth pitches US-Asean defence framework but will it be a hard sell?
US Defence Secretary Pete Hegseth on Wednesday proposed a new US-Asean defence framework to guide cooperation over what he called “critically important years” ahead, but offered few details on what it would entail. The proposal faces questions over whether members of the Association of Southeast Asian Nations will embrace a bloc-wide initiative, with analysts suggesting they would prefer bilateral arrangements that preserve their flexibility as they navigate ties with Washington and...
‘Not to find scapegoats’: Singapore ministers summon bosses of 10 firms over haze
In a rare move, Singapore on Wednesday summoned top executives from 10 locally registered companies potentially linked to haze-causing fires in Indonesia to a meeting with three ministers. The executives all agreed to cooperate fully in an investigation by the city state into the regional environmental crisis that has caused air quality to dip to “very unhealthy” levels earlier this month. Deputy Prime Minister Gan Kim Yong, Senior Minister K. Shanmugam and Minister for Sustainability and the...
Can Singapore Help Europe Rethink Its Indo-Pacific Strategy?
Singapore has spent decades making itself indispensable to a global economy in which it has little control over the behavior of the major powers. Germany might be seeking to learn from that example.
Will Pakistan Fight in Saudi Arabia’s Wars?
Questions have been raised over the strength of Pakistan’s security commitment to Saudi Arabia ever since the SMDA’s inception in September 2025.
Jio’s Blockbuster I.P.O. Gives India’s Investors a Lift
Jio Platforms shares surged on their first day of trading, even as questions mount about the telecom firm’s growth prospects and a new generation takes charge.
Kyrgyzstan Temporarily Bans Imports of Apples (and More)
The EU – which is the top exporter of apples to Kyrgyzstan – urged Bishkek against the ban, noting that WTO rules require “exceptional circumstances” to justify such measures.
Why Are Russia and China Cooperating on ‘Patriotic Education’?
China has decades of experience in “patriotic education.” What it can learn from Russia is how to use education to support a war effort.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.